TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05626790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: All participants will join an exercise program that will last 20-30 minutes, 5 days a week for 4 weeks, especially targeting proximal stabilization. The exercise program is expected to take 20-30 minutes. Each exercise will be done in 3 sets. Each set will include 10 repetitions. In weight-bearing exercises, the participant will be asked to hold the position for 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Stretching
Description: In addition to the exercises, three different PNF stretching will be applied to the participants in the PNF stretching group for 4 weeks, 5 days a week.~1. Biceps: Flex-Add-ER repositioned half pattern~2. Brachioradialis: Flex-Abd-ER repositioned half pattern~3. Brachialis: Ext-Add-IR half pattern In the supine position, the physiotherapist will move the forearm to the end of the passive range of motion according to the direction of limitation. Secondly, participants will be asked to perform a submaximal isometric contraction of the target muscle with an emphasis on rotation for 10 seconds. After this contraction, participants will be asked to relax for 5 seconds. In the third phase, the elbow joint will be actively repositioned to the new range of motion, and the physical therapist will help to the patient to keep this position for an additional 10 seconds. This procedure will be repeated 10 times with a 10 secs resting period between two consecutive stretches.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Stretching
Description: In addition to the exercises given to both of the groups, static stretching will be applied to the elbow flexors in 2 different positions for 4 weeks, 5 days a week. Participants will need to complete 5 sets of 1.5-minute stretching and 30-second rest periods for both of the two stretching positions listed below. The total duration of the stretches to be performed together with the rest periods will be 20 minutes.~1. In supine position, the shoulder will be positioned in 90° abduction and internal rotation, the forearm will be positioned in pronation, then the shoulder will be slowly extended. In this way, especially the Biceps Brachii and Brachioradialis muscles are expected to be stretched.~2. In supine position, the shoulder will be positioned in 90° abduction and maximum external rotation, and the forearm will be positioned in full supination. In this way, especially the brachialis muscle is expected to be stretched.
Study: NCT05701306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: Orally once every other day(QOD) for 2 weeks and suspended for 1 week, 21 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: Orally once a day (QD) for 21 days, 21 days as a cycle.
Study: NCT04576650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summit System
Description: Surgical implantation of the Summit system (consisting of one or two Medtronic Activa(R) RC+S grids with wireless communication capabilities) for Safety and efficacy testing of the Medtronic Summit System.
Study: NCT04949061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behavioral Intervention (CA-CBI)
Description: CA-CBI is an intervention based on Culturally Adapted Cognitive Behavioral Therapy (CA-CBT) which was developed by Devon Hinton. This trans-diagnostic intervention has a structured manual which can be culturally adapted and it will be used to decrease psychological distress and increase quality of life by targeting cognitive and behavioral changes.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment as Usual (ETA-U)
Description: Participants who receive ETAU will be provided a brief psychoeducation via online leaflets and will be informed about centers where they can receive free psychosocial support.
Study: NCT04403568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Ursolic Acid 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursolic Acid
Description: Ursolic Acid 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600mg
Study: NCT05672420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived mesenchymal stem cells
Description: umbilical cord derived mesenchymal stem cells, intravenous infusion
Study: NCT04702698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive single oral dose of Peposertib tablet under fasting (Treatment A) or fed (Treatment B) conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Participants will receive oral suspension dose of peposertib tablets under fasted condition (Treatment C) in either period 1, 2 or 3 of part 1.
Study: NCT05031000

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement: POCT
Description: measurement of blood glucose concentration using 5 different POCT glucometer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement: reference
Description: measurement of blood glucose concentration using 2 different laboratory analyzer
Study: NCT06069310

Intervention type: DRUG
Intervention: Mepolizumab 100 MG
Description: Monthly administartion of mepolizumab 100mg

Intervention type: DRUG
Intervention: Mepolizumab 100 MG
Description: Monthly administartion of mepolizumab 100mg
Study: NCT04522622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: 20 micrograms

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT
Description: All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 12 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 12 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.
Study: NCT04818944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be dosed for 24 hours post MT via continuous IV
Study: NCT05702008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rabies Information Education and Communication Material
Description: The test group was administered the rabies IEC material available on the National Center for Disease Control (NCDC) website (https://ncdc.gov.in/index1.php?page=1\&ipp=All\&lang=1\&level=2\&sublinkid=502\&lid=428) in English and Hindi languages using a WhatsApp broadcast every 3 days for 30 days, in a cyclical manner. This material includes brochures, posters, short films, and informative documents designed to educate the general public about rabies prevention and post-exposure prophylaxis practices. Text messages, encouraging the participants to go through the material, were also a part of this intervention.
Study: NCT05517629

Intervention type: OTHER
Intervention: It is an observational cross-sectional study
Description: It is an observational cross-sectional study

Intervention type: OTHER
Intervention: It is an observational cross-sectional study
Description: It is an observational cross-sectional study

Intervention type: OTHER
Intervention: It is an observational cross-sectional study
Description: It is an observational cross-sectional study

Intervention type: OTHER
Intervention: It is an observational cross-sectional study
Description: It is an observational cross-sectional study
Study: NCT04522622

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT
Description: All participants undergo DXA and VFA or X-ray scans 3 times during the study. Some participants (those connected to Herlev) are offered 18F NAF PET/CT scans at baseline and after 12 months and some participants (those connected to Odense University Hospital and Aalborg University Hospital) are offered HR-pQCT scans at baseline and after 12 months. The 18F-NAF PET/CT and HR-pQCT are optional, so it is not a must to have these procedures done to participate in the study.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone biopsy
Description: All participants are invited to undergo a bone biopsy after 12 months, but it is not a must to have the procedure done to participate in the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone biopsy
Description: All participants are invited to undergo a bone biopsy after 12 months, but it is not a must to have the procedure done to participate in the study.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac tests
Description: All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac tests
Description: All participants are invited to undergo 24-hour blood pressure measurements and pulse wave measurements at baseline and after 18 months, but it is not a must to have these procedures done to participate in the study.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood and urine samples and physical examination
Description: All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and urine samples and physical examination
Description: All participants must undergo a physical examination and deliver blood and urine samples in order to participate in the study.
Study: NCT05341401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide MMX
Description: Budesonide MMX is a second generator corticosteroid with prolonged colonic release used for management of ulcerative colitis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: It is a corticosteroid used as a standard therapy for management of ulcerative colitis
Study: NCT04885985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB catheter
Description: Trade name of DEB catheter: AcoArt Tulip (0.018) or AcoArt Litos (0.014)
Study: NCT05839717

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: A specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
Study: NCT04654026

Intervention type: DRUG
Intervention: Aspirin/Clopidogrel
Description: No intervention, only observational studies

Intervention type: DRUG
Intervention: Aspirin/Clopidogrel
Description: No intervention, only observational studies
Study: NCT06629181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The researchers will conduct a 4-week intervention for the intervention group participants.~Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training
Study: NCT05684549

Intervention type: OTHER
Intervention: No intervention
Description: Observational study, no intervention
Study: NCT05518617

Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) scan using DASB tracer
Description: DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,

Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) scan using DASB tracer
Description: DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,

Intervention type: OTHER
Intervention: Positron Emission Tomography (PET) scan using DASB tracer
Description: DASB is a highly selective PET radioligand for serotonin transporter and is a reliable tool to investigate serotonin terminals and neurons.~The included Magnetic Resonance Imaging (MRI) sequences serve to provide additional information plus complement PET data.~To quantify dopaminergic pathology with \[123I\]FP-CIT SPECT,
Study: NCT05007925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: Localized peripheral intravascular lithotripsy
Study: NCT05877716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive and Social Cognitive Training
Description: The Cognitive Training Module is designed to improve the speed and accuracy of auditory information processing while engaging working memory and cognitive control under conditions of close attention and reward. The goal is to increase the effectiveness by which salient stimuli engage and drive plastic changes in brain systems that in individuals with psychosis exhibit relatively poor temporal response.~The Social Cognition Training Module consists of exercises designed to ameliorate core deficits in social cognition expressed in schizophrenia and Autism Spectrum Disorders. The exercises apply principles of implicit learning to restore the brain's capacity to process and utilize socially-relevant information, and include training to improve affect perception, social cue perception, theory of mind, self-referential style, and emotion labeling and working memory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App
Description: The PRIME smartphone-based app is designed to be used for 12 weeks to enhance motivation in people with early psychosis. Participants work towards self-identified goals with the support of the virtual community of age-matched peers, as well as with motivation coaches. Participants discuss their interests and aspirations with each other and with their coach, and the coach sends daily individualized motivational messages. Coaches also provide tailored interventions to enhance motivation, and post daily discussion topics to the PRIME community to encourage interaction between members. Coaches will maintain close communication and feedback on progress with each individual's clinical team.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Psychosis Coordinated Specialty Care
Description: Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Psychosis Coordinated Specialty Care
Description: Participants will continue to engage in treatment as usual at their early psychosis coordinated specialty care clinic. These clinics may follow the NAVIGATE model, as an example.
Study: NCT04823676

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic composition
Description: Mixture of two Lactoplantibacillus plantarum strains (formerly Lactobacillus plantarum) and one Levilactobacillus brevis strain (formerly Lactobacillus brevis), in a maltodextrin carrier (E1400)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (E1400, qs)
Study: NCT06307106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac and light marcaine
Description: local injection at surgical site of 30 mg ketorolac and 7-1.5 mg\\kg\\dose light marcaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: light marcaine
Description: local injection at surgical site of 7-1.5 mg\\kg\\dose light marcaine
Study: NCT05986123

Intervention type: OTHER
Group type: OTHER
Intervention: Topical cream Z for PIH
Description: The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
Study: NCT05251584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Apply mupirocin ointments for prevention of peritoneal dialysis-related infection between 1 January 2021 to 31 December 2021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Apply gentamicin creams for prevention of peritoneal dialysis-related infection for 1 year start after 1 January 2022
Study: NCT04758455

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P53, Ki67 and Cyclin A IHC.
Description: P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P53, Ki67 and Cyclin A IHC.
Description: P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P53, Ki67 and Cyclin A IHC.
Description: P53, Ki67 and Cyclin A immunohistochemical staining of formalin-fixed paraffin-embedded specimens of Wilms' tumour.
Study: NCT06307106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids injection
Description: local injection at surgical site of 40 mg\\ dose of dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium Gel
Description: topical application of Diclofenac Sodium Gel
Study: NCT05570448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ARAT
Description: For patients randomized to ARAT intervention, the area of cardia, along greater curvature will be cleaned followed by demarcation of a 1-1.5 cm area of non-ablation zone with two vertical lines by use of Pulsed APC (30W, Effect 2) using the H-APC catheter. Next, the area of cardia, on either side will be injected in sequence using a methylene blue (0.5%) and normal saline (0.9%) using the H-APC catheter jet system (Effect 30-70). Next, the mucosa, starting below the z-line and up to 3 cm below will be treated by Pulsed APC 50W-80W till golden-brown discoloration of the ablated tissue in 270-320 degree. For patients randomized to control or sham intervention, upper endoscopy with procedural sedation was performed followed by markings of landmarks followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time. No H-APC or submucosal injection or other intervention will be performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention (control)
Description: Patients randomized to the control arm, will undergo a sham intervention. This will include performing upper endoscopy with procedural sedation followed by markings of landmarks as described. This will be followed by gastroscope retroflexion in the gastric cardia with at least 15 minute of examination time spent in retroflexion to reciprocate the H-APC intervention. No H-APC or submucosal injection or other intervention will be performed during the upper endoscopy with sham intervention. All Patients will also continue their PPI daily for 4 weeks.